32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. (4th August 2020)

• Record Type: Journal Article
• Authors: Galldiks, Norbert; Abdulla, Diana; Scheffler, Matthias; Wolpert, Fabian; Werner, Jan-Michael; Hüllner, Martin; Stoffels, Gabriele; Schweinsberg, Viola; Schlaak, Max; Kreuzberg, Nicole; Landsberg, Jennifer; Lohmann, Philipp; Ceccon, Garry; Baues, Christian; Trommer, Maike; Celik, Eren; Ruge, Maximilian; Kocher, Martin; Marnitz, Simone; Fink, Gereon; Tonn, Jörg-Christian; Weller, Michael; Langen, Karl-Josef; Wolf, Jürgen; Mauch, Cornelia
• Is Part Of: Neuro-oncology advances. Volume 2(2020)Supplement 2
• Page Start: ii5
• Page End: ii6
• Publication Date: 2020-08-04
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdaa073.020
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: PURPOSE: Recently, the RANO group has analyzed the additional diagnostic value of amino acid PET in patients with primary and secondary brain tumors and recommended the use of this imaging technique in addition to conventional MRI. Here, we investigated the value of PET using the radiolabled amino acid O-(2-[ 18 F]fluoroethyl)-L-tyrosine (FET) for treatment monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in combination with radiotherapy in patients with brain metastases (BM) since contrast-enhanced MRI often remains inconclusive. METHODS: We retrospectively identified 40 patients with 107 BM secondary to melanoma (n=29 with 75 BM) or non-small cell lung cancer (n=11 with 32 BM) treated with ICI or TT who had FET PET (n=60 scans) for treatment monitoring from 2015–2019. The majority of patients (n=37; 92.5%) had radiotherapy during the course of disease. In 27 patients, FET PET was used for the differentiation of treatment-related changes from BM relapse following ICI or TT. In 13 patients, FET PET was performed for response assessment to ICI or TT using baseline and follow-up scans (median time between scans, 4.2 months). In all lesions, static and dynamic FET PET parameters were obtained (i.e., mean tumour-to-brain ratios (TBR), time-to-peak values). Diagnostic accuracies of PET parameters were evaluated by receiver-operating-characteristic analyses using the clinical follow-up or neuropathological findings as reference. RESULTS: A TBR threshold of 1.95 differentiated BM relapse from treatment-related changes with an accuracy of 85% ( P =0.003). Metabolic Responders to ICI or TT on FET PET had a significantly longer stable follow-up (threshold of TBR reduction relative to baseline, ≥10%; accuracy, 82%; P =0.004). Furthermore, at follow-up, time-to-peak values in metabolic responders increased significantly ( P =0.019). CONCLUSIONS: FET PET may add valuable information for treatment monitoring in BM patients treated with ICI or TT.